East Tennessee State University

Digital Commons @ East Tennessee State University
Undergraduate Honors Theses

Student Works

5-2017

Effect of Cannabinoids on Osteogenic
Differentiation of Cultured Vascular Smooth
Muscle Cells
Bree A. Eccles
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/honors
Part of the Cardiovascular Diseases Commons
Recommended Citation
Eccles, Bree A., "Effect of Cannabinoids on Osteogenic Differentiation of Cultured Vascular Smooth Muscle Cells" (2017).
Undergraduate Honors Theses. Paper 392. https://dc.etsu.edu/honors/392

This Honors Thesis - Withheld is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University.
It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of Digital Commons @ East Tennessee State
University. For more information, please contact digilib@etsu.edu.

Effect of Cannabinoids on Osteogenic Differentiation of Cultured Vascular Smooth
Muscle Cells

By

Bree Eccles

An Undergraduate Thesis Submitted in Partial Fulfillment
of the Requirements for the
Honors-in-Discipline Chemistry Program and
Midway Honors Scholars Program
College of Arts and Sciences
East Tennessee State University

Bree Eccles

Date

Dr. Douglas P. Thewke, Thesis Mentor

Date

Dr. Antonio E. Rusiñol, Reader

Date

Dr. Karen Kornweibel, Reader

Date

Contents

Introduction

1

Atherosclerosis

1

The Endocannabinoid System

4

Justification and Objective

7

Materials and Methods

8

Cell Culture

8

Osteoblast De-differentiation

8

Treatment with Synthetic Cannabinoids

8

Preparation of Cell Lysates

9

Western Blotting

9

Alizarin Red Staining

10

Quantitation of Alizarin Red Staining

10

Image Analysis using ImageJ Software

11

Statistical Analysis

11

Results

12

Discussion

19

Acknowledgements

22

References

23

Introduction
Atherosclerosis
Atherosclerosis is a chronic inflammatory vascular disease characterized by the
formation of cholesterol-filled lesions within the arterial wall. The formation of raised,
often calcified lesions in the arterial intima leads to narrowing of vessels and blockage
of blood flow, reducing arterial compliance [1]. Heart disease, specifically
atherosclerosis, is the leading cause of morbidity and mortality on a global scale [2]. A
large risk factor for this disease is an increased blood concentration of primarily lowdensity lipoproteins (LDL), so called “bad cholesterol” [2]. However, this disease often
coincides with other risk factors including smoking, hypertension, diabetes mellitus, the
male sex, and a genetic history of the disease [2].
The formation of atherosclerotic lesions begins when low-density lipoprotein
(LDL) crosses the lining of the endothelium and becomes oxidized to form OX-LDL
within the arterial wall [3]. Monocytes are recruited to the area and transform into
macrophages that engulf the lipoproteins and form foam cells – the signature of
atherosclerosis [3]. Ingestion of oxLDL induces macrophage apoptosis, or programmed
cell death. The buildup of cellular debris from apoptosis and other materials in the
vessel wall forms the atherosclerotic lesion. Foam cells combine with leukocytes to
become a fatty streak, and as the process continues, foam cells secrete proinflammatory growth factors that induce smooth muscle cells to migrate into the area [3].
These vascular smooth muscle cells (VSMC) secrete extracellular matrix components to
help stabilize the lesion. As the lesion progresses, it may become calcified by
mechanisms involving the trans-differentiation of VSMC into osteoblast-like cells, thus
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forming a plaque. A plaque is considered stable when the lipid core is covered by a
thick SMC-saturated fibrous cap. If the fibrous cap weakens and ruptures, the
underlying materials will interact with platelets and coagulation factors and form a
thrombosis (a blood clot). The thrombus that forms may dislodge and cause blockage
of blood flow. The blockage of blood flow presents serious health risks – the deprivation
of oxygen to downstream tissue leads to the clinical manifestations of atherosclerosis,
heart attacks and strokes [4]. The formation of an atherosclerotic lesion is
demonstrated in Figure 1 below:

Figure 1: Development of an atherosclerotic lesion [3]. This process begins when LDL (so called bad
cholesterol) enters the subendothelial space. LDL becomes oxidized to form oxLDL. Monocytes are
recruited to the area and differentiate into macrophages in the subendothelial space. After the
macrophages engulf the LDL, this causes an increase of intercellular cholesterol and this creates a foam
cell. The foam cells and other immune cells release growth factors which recruit more macrophages,
which become more foam cells. Vascular smooth muscle cells (VSMC) are recruited to the area and
overlay the lesion. VSCM secrete ECM components to help stabilize the lesion. As the lesion progresses
it may become calcified by mechanisms involving the trans-differentiation of VSMC into osteoblast-like
cells. This creates a plaque. If a plaque becomes unstable and ruptures a thrombosis composed of
platelets can form and break off and cause blockage leading to heart attacks and strokes. This figure was
obtained from “Oxidative Stress and Vascular Disease” by Nageswara R. Madamanchi, Aleksandr
Vendrov, and Marschall S. Runge. [3]
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The calcification of vasculature is strongly correlated with the clinical
manifestations of atherosclerosis. It is thought that calcification in arteries occurs in a
process similar to skeletal bone remodeling and involves the osteogenic transdifferentiation of SMC within the walls of arteries that induces an active cell-mediated
program that modulates deposition of bone matrix in blood vessels [5]. This process
contains similar cells to osteoclasts (bone-destroying cells) and osteoblasts (boneforming cells). Osteoblast-like cells are derived from trans-differentiated VSMC and are
triggered by oxidative stress and the presence of phosphate [6]. Calcification occurs
when the balance between osteoblasts and osteoclasts is not maintained, resulting in
more calcium deposition than uptake. However, a complete understanding of the
atherosclerotic calcification process is still unknown.
In calcified blood vessels, bone-related transcription factors including runt-related
transcription factor 2 (RUNX2), and osterix (OSX) have been detected in populations of
smooth muscle cells [5]. These transcription factors upregulate bone and chondrocyte
proteins and control processes critical for osteoblast differentiation [5]. RUNX2 is
required for early commitment of progenitor cells to differentiate into osteoblasts [7].
Osterix (OSX) is an osteoblast-specific transcription factor that acts downstream of
RUNX2 [8]. Gene deletion studies have shown through the absence of RUNX2 or OSX,
that these transcription factors are essential for osteoblast differentiation [9].
Osteoblasts are also an important marker in advanced atherosclerotic lesions.
Osteoblastic activity can be detected by measuring calcium deposition, because
osteoblasts are calcium-depositing cells. Osteopontin (OPN) is a protein that serves as
a regulator for bone remodeling and is a potent inhibitor of vascular calcification [10].
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OPN is expressed in the mineralized bone matrix, in macrophages, endothelial cells,
smooth muscle cells and epithelial cells and serves as a marker of atherosclerotic
calcification and indicates the presence of mature, calcium depositing osteoblasts [10].
Figure 2 below demonstrates the timeline of a progenitor cell transforming into a
committed osteoblast, to a mature osteoblast and finally into an osteocyte. The figure
also illustrates where in the process the markers (RUNX2, OSX and OPN) can be
detected.

Figure 2: Timeline of a progenitor cell to an osteocyte and the position of the
osteogenic markers in the process.

The Endocannabinoid System
Cannabinoids are molecules that are structurally similar to Δ9 tetrahydrocannabinol (THC), the primary psychoactive component in marijuana.
Beginning from the known effects of smoking marijuana on heart rate and blood
pressure, the cardiovascular effects of this compound were further investigated [11].
Since its discovery, the endocannabinoid system’s role as a key signaling system has
been found to take a part in nearly all physiological and pathological functions in
mammals [11]. The endocannabinoid system has been shown to play a role in a wide
4

variety of processes including: memory, appetite, metabolism, stress and anxiety,
analgesia, thermoregulation, sleep and immune cell function [12].
The endocannabinoid system comprises two distinct membrane G-proteincoupled receptors that have been identified by molecular cloning [13]. These two
receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2)
and their endogenous ligands (called endocannabinoids) make up the endocannabinoid
system. The CB1 receptor is primarily located in the central nervous system (brain and
spinal cord) where it moderates the neurological and psychotropic effects of
cannabinoids, but is also found in peripheral tissues and immune cells [13]. The CB2
receptor is predominantly expressed in peripheral immune cells [14]. It is believed that
the immunomodulatory effects of cannabinoids are mediated by CB2 receptors
expressed on immune cells [13]. Our lab has previously shown that mice lacking the
CB2 receptor develop more calcification plaques compared to wild type mice with the
CB2 receptor. However, both receptors have been identified outside of their primary
locations – including in vascular smooth muscle cells [11].
In addition to the CB1 and CB2 receptors, the endogenous ligands that activate
these receptors (known as endocannabinoids) are a key part of this system.
Endocannabinoids, such as anandamide (N-arachidonoyl-ethanolamine, AEA) and 2arachidonoylglycerol (2-AG), are biologically active fatty acids that have been shown to
present a therapeutic target for the treatment of hypertension, a major risk factor for
atherosclerosis [13]. AEA is a partial agonist at the CB1 receptor and is a weak partial
agonist at CB2. 2-AG is considered a full agonist toward the CB2 receptor [12]. Both
AEA and 2-AG are synthesized locally and on demand from membrane phospholipids
5

and are subject to rapid turnover, which limits their signaling to autocrine and paracrine
mechanisms [12]. Both CB1 and CB2 have been shown to affect the formation of
atherosclerotic lesions in studies of animal models [11] [15].
In contrast to the endogenous agonists, a known antagonist of these receptors is
SR-144,528. A synthetic cannabinoid, SR-144,528, is characterized as a highly potent,
selective and orally active antagonist for the CB2 receptor [16]. In an experimental
mouse model of atherosclerosis, administration of low-dose THC resulted in the
significant inhibition of plaque development, an effect that could be reversed by the coadministration of SR-144,528 [13].
As atherosclerosis was further understood as an inflammatory disease of the
vasculature, studies investigating the possibility of an immunoregulatory effect of
atherosclerosis by the endocannabinoid system have increased. In animal models,
CB1 and CB2 have been shown to affect the formation of atherosclerotic lesions [11].
Generally, CB1 and CB2 have opposite effects. For example, CB1 activation often
provides a pro-inflammatory and pro-atherosclerotic effect and activation of CB2
induces the opposite effect. Both receptors have also been implicated in having a role
in the regulation of bone mass and bone remodeling through altering differentiation of
precursor cells [17]. Mice lacking the CB2 receptor have been shown to have an
accelerated age-related bone loss, which is similar to osteoporosis in humans [18]. As
bone loss is inversely correlated with calcification in atherosclerotic lesions, these
results further suggest that the CB2 receptor may play a role in the calcification process
in atherosclerotic plaques.
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Justification and Objective
We hypothesized that endocannabinoids modulate calcification of plaques by
affecting osteogenic trans-differentiation of vascular smooth muscle cells (VSMC).
Cannabinoid receptors are known to modulate bone formation and are present in
elevated levels in atherosclerotic lesions and vessels, which lead us to suggest that
they may also play a role in modulating calcification of these lesions. To begin to test
this hypothesis, we evaluated the effects of two endocannabinoids (2Arachidonoylglycerol and Anandamide) on the expression of osteogenic marker
proteins by VSMC undergoing trans-differentiation to osteoblast-like cells.
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Materials and Methods
Cell Culture
A transformed murine vascular smooth muscle cell line (MOVAS-1) was
purchased from the American type culture collection (ATCC, VA, USA). MOVAS-1 cells
were maintained in modified Dulbecco’s Modified Eagle Medium (DMEM) (ATCC #302002) containing 4.5 g/L D-Glucose, 1.5 g/L sodium bicarbonate and supplemented with
10% fetal bovine serum, 0.2 mg/ml G-418, and 1% penicillin-streptomycin. The cells
were maintained in a 5% CO2 / 95% air humidified incubator.
Osteoblast Trans-differentiation
MOVAS-1 cells were seeded at 100,000 cells per plate in 35mm tissue culture
dishes containing 2 mL of standard growth media. The media was replaced every other
day until the cells reached a confluent monolayer in the dish, usually 24-48 hours after
plating. Once confluent, the standard media was then replaced with osteogenic media
(standard media supplemented with 2.6 mM Phosphate, pH 7.4). Controls were
maintained in standard growth media. The cells were re-fed osteogenic media every
two or three days as necessary. After 3-7 days of treatment, calcium deposition and
expression of osteogenic marker proteins were evaluated by Alizarin Red staining and
western blotting, respectively.
Treatment with Synthetic Cannabinoids
Once confluent, the cells were switched to osteogenic media supplemented with
endocannabinoids. Supplements of 2-Arachidonylglycerol (2-AG) and/or anandamide
(AEA) (Tocris Bioscience, Bristol, UK) and SR-144,528 (Biomol, Hamburg, DE) were
8

added to the osteogenic media. Treatments containing endocannabinoids (2AG, AEA)
were present at 5 µM concentrations and treatments containing SR-144,528 were
present in 2 µM concentrations. Controls received equal amounts of vehicle (DMSO).
The media was replaced every 2-3 days as needed.
Preparation of Cell Lysates
The cells were washed twice with phosphate buffered saline (PBS) and collected
in ice-cold 1X cell lysis buffer (Cell Signaling Technology, MA, USA) supplemented with
Protease Inhibitor Cocktail (Thermo Scientific, MA, USA). The cells were kept at 4°C for
10 minutes and then centrifuged for 15 minutes at 12,000 x g at 4°C. The protein
concentrations of the supernatants were determined by micro-BCA assay (Thermo
Scientific, MA, USA) with BSA as the standard. The protein concentration was
compared to the standard curve of known concentrations to determine the protein
concentration of the samples. Cell lysates were stored at -80°C until use.
Western Blotting
Equal amounts (20 µg) of cell lysates were subjected to SDS-PAGE on 4-12%
Bis-Tris NuPAGE gels (Life Technologies, CA, USA) and transferred to polyvinylidene
fluoride membranes. The membranes were blocked in tris buffered saline containing
0.2% Tween-20 (TBS-T) and 5% nonfat dry milk for 1 hour followed by overnight
incubation at 4°C in TBS-T containing a 1:1000 dilution of a primary antibody: AntiRUNX2 (Santa Cruz Biotechnology, Dallas, TX), Anti-OPN (R30 Systems, Minneapolis
MN), Anti-OSX (Aviva Systems Biology, San Diego, CA). The membranes were washed
5 times with TBS-T and then incubated for 1 hour with an HRP-conjugated secondary

9

antibody. After washing 5 times with TBS-T, the bands were visualized using an ECL
Prime Western Blotting Detection Reagent (GE Healthcare, Pittsburg, PA) and a LAS4000 image analyzer (GE Healthcare, Pittsburg, PA). To control for equal protein
loading and transfer, the membranes were rinsed with TBS-T and subjected to the
immunoblotting procedure using a 1:1000 dilution of a primary antibody to ß-actin
(ProSci, San Diego, CA). Densitometry analysis of the relative band densities was
performed using NIH ImageJ software. The results were normalized to ß-actin to
correct for slight variations in protein loading and transfer efficiency.
Alizarin Red Staining
Alizarin Red staining was performed to stain the cell matrix monolayer for
calcium deposits. The media was aspirated from the plates and phosphate buffered
saline (PBS) was used to wash the cells twice. The cells were then fixed with 10%
buffered formalin for 10 minutes and subsequently rinsed with PBS. The cells were
then stained with a 2% Alizarin Red solution (Electron Microscopy Sciences, Hatfield,
PA) for 30 minutes, followed by three 1-minute rinses with distilled water. After staining,
the cells were digitally photographed.
Quantitation of Alizarin Red Staining
After digital photography of the Alizarin Red stained cells, the bound Alizarin Red
was extracted from the cells by incubating in 2 mL of 10% cetylpyridinium chloride. The
absorbance at 562 nm was then measured using a microplate reading
spectrophotometer to quantify the amount of extracted dye from each plate.
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Image Analysis using ImageJ Software
Quantification of the resultant bands from the Western blots and analysis of the
degree of alizarin Red staining in digital images was performed using computer-assisted
morphometric analysis software (ImageJ, NIH). For quantification of Alizarin Red
staining, 4X photomicrographs were obtained using a light microscope equipped with a
charge coupled device (CCD) camera attached to a PC. Photomicrographs (4X) were
taken at 3 random microscopic fields and analyzed using ImageJ by thresholding for the
red pixel color. The thresholding parameters were held constant for all images
examined and the results were expressed as the area of the image occupied by red
divided by the total area of the image. To quantify the Western blot bands, digital
images of the blots were evaluated using the standard procedure from NIH. The optical
density recorded for each band was normalized to the optical density of the
corresponding band for ß-actin. The ratio obtained for the standard media sample was
set as 1.0 and used to calculate the fold difference. The data was then presented as
the mean ± S.D. of three replicate western blots.
Statistical Analysis
Student t-tests were performed using SPSS Version 12.0 statistic software
package. P-values < 0.05 were considered statistically significant.
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Results
To begin to access the potential effect of endocannabinoid supplementation on
osteogenic trans-differentiation of vascular smooth muscle cells, MOVAS-1 cells were
cultured in osteogenic media (2.6 mM Pi) containing 2-Arachidonylglycerol (2-AG),
anandamide (AEA), 2-AG and AEA together, or 2-AG, AEA and SR-144,528, a CB2
selective antagonist. After 3 and 5 days of treatment, the MOVAS-1 cells were stained
with Alizarin Red to access the degree of calcium deposition (Figures 3 and 4). The
trends seen in Figure 3 and 4 demonstrate that calcification is a time dependent
process – with photographs taken at 5 days exhibiting a higher degree of positive
staining than the photos taken at 3 days. Supplementation with 2-AG or AEA alone,
and in combination, resulted in visibly more calcium deposition compared to the cells
cultured in osteogenic media alone. However, co-treatment with SR-144,528 did not
appear to alter the degree of calcium deposition in response to 2-AG and AEA.
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Figure 3: MOVAS-1 cells stained with Alizarin Red. After treatment, the MOVAS-1 cells were
stained with Alizarin Red. The treatment groups are listed horizontally indicating standard growth
media (Std), osteogenic media (2.6 mM Pi), 5 µM 2-AG alone (2AG), 5 µM AEA alone (AEA), 5
µM of both endocannabinoids in combination (2AG+AEA), as well as the combination of 5 µM of
2-AG and AEA with the addition of 2 µM SR-144,528 (2AG+AEA+SR). The top panel shows
results of cells treated for 3 days. The bottom panel shows results of cells treated for 5 days.

Figure 4: Photomicrographs of Alizarin Red stained MOVAS-1 cells. Corresponding to the
same Alizarin Red stained plates from Figure 3, three random microscopic fields were
photographed at 4X magnification. The top panel indicates staining results from the 3-day
treatment group. The bottom panel demonstrates results from the 5-day treatment group.
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To quantify the degree of Alizarin Red staining present in the figures above, two
methods were employed. First, the amount of Alizarin Red stain bound to the plate was
evaluated by computer assisted morphometric analysis of digital photomicrographs to
measure the percent of the total area stained by Alizarin Red. The results, presented in
Figure 5, revealed that supplementation with 2-AG or AEA alone produced a statistically
significant (p < 0.05) increase in calcium deposition at 3 days when compared to the
corresponding osteogenic media only treatment, but only the 2-AG group was
significantly greater after 5 days. Treatment with both AEA and 2-AG also resulted in a
statistically significant increase in calcium deposition after 5 days. However, cotreatment with SR-144,528 did not have a statistically significant effect on induction of
calcium deposition by 2-AG and AEA.
A second method was utilized to verify the results of the digital quantitation of the
Alizarin Red staining. The bound Alizarin Red was extracted with 10% cetylpyridinium
chloride and the absorbance of the Alizarin Red dye extracted from each plate was
measured spectrophotometrically at 562 nm (Figure 6). The results obtained with this
method are in general agreement with those for the digital quantification methods
shown in Figure 5. However, both 2-AG and AEA alone as well as in combination
produced statistically significant results at 3 and 5 days. The results also indicated that
the when the endocannabinoid combination (2-AG+AEA) was compared to the
combination with SR-144,528 added, the results were not statistically significant (p <
0.05).
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* = p < 0.05 vs. Pi
Figure 5: Quantitation of calcium deposition detected by Alizarin Red staining using
computer assisted morphometric analysis. The area occupied by red pixels present in three
random photomicrographs shown in Figure 3 was obtained by thresholding for the area occupied
by red and dividing by the total area of the digital image. The results are presented as the mean
percent calcification ± the standard deviation (SD) of three random fields. Asterisks (*) indicate p
< 0.05 compared to cultured osteogenic media (Pi) alone.

* = p < 0.05 vs. Pi
** = p < 0.001 vs. Pi
NS = not statistically
significant

Figure 6: Quantitation of calcium deposition by extraction of Alizarin Red with
cetylpyridinium chloride. Alizarin Red bound to each plate was extracted using 10%
cetylpyridinium chloride and the absorbance was determined spectrophotometrically at 562 nm.
The results are presented as the mean ± the standard deviation (SD) of three replicate
treatments. Asterisks (*) indicates p < 0.05 and (**) indicates p < 0.001 compared to cultured
osteogenic media (Pi) alone.
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Three osteogenic marker proteins were examined to investigate the effects of
endocannabinoid treatment on the osteogenic trans-differentiation of the MOVAS-1 cells
at the molecular level. These markers include Runt related transcription factor 2
(RUNX2), Osteopontin (OPN), and Osterix (OSX). From the western blots (Figure 7)
and subsequent graphs (Figures 8-10), it can be observed that expression of OSX and
RUNX2 varied only slightly with the addition of endocannabinoids and with addition of a
CB2 inhibitor. However, OPN levels were strikingly induced by the addition of 2-AG and
AEA alone and more so when used in combination. The induction of OPN expression
was greatly reduced by co-treatment with SR-144,528, indicating a CB2-dependent
effect by 2-AG/AEA on expression of OPN. In contrast, co-treatment with SR-144,528
had little or no effect on the expression levels of OSX and RUNX2.

Figure 7: Expression of osteogenic marker proteins in MOVAS-1 cells. Following 7 days of
endocannabinoid treatment, cell lysates were prepared and analyzed by western blotting to
compare the expression levels of OSX, RUNX2, and OPN. Beta actin expression was also
evaluated as a loading control. The labels at the top of the figure correspond to standard growth
media (Std), osteogenic media (2.6 mM Pi), 5 µM 2-AG, 5 µM AEA, 5 µM of both 2-AG and AEA
in combination (2AG+AEA), and the 5 µM combinations with the addition of 2 µM SR-144,528
(2AG+AEA+SR). Results shown are representative of three western blotting experiments.
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Figure 8: RUNX2 expression levels following 7 days of endocannabinoid treatment. The
ratio of RUNX2 to ß-actin was determined by quantifying the relative band densities and
compared to the value determined for MOVAS-1 cells cultured in standard media alone to give
the fold induction. The results are presented as the mean ± the standard deviation of three
western blot experiments.

Figure 9: OSX expression levels following 7 days of endocannabinoid treatment. The ratio
of OSX to ß-actin was determined by quantifying the relative band densities essentially as
described for Figure 8. The results are presented as the mean ± the standard deviation of three
western blot experiments.
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Figure 10: OPN expression levels following 7 days of endocannabinoid treatment. The ratio
of OPN to ß-actin was determined by quantifying the relative band densities essentially as
described for Figure 8. The results are presented as the mean ± the standard deviation of three
western blot experiments.
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Discussion
Currently, atherosclerosis is the leading cause of death in the United States. The
current treatment options primarily target only the risk factors for atherosclerosis – such
as aiming to inhibit high cholesterol levels, diabetes mellitus, obesity, and hypertension.
The calcification seen in advanced atherosclerotic lesions is strongly correlated with
increased risk for myocardial infarction (heart attacks) and strokes. There is no known
cure for atherosclerosis, the best therapies merely help slow the formation of plaques
but cannot prevent their formation or calcification. This is largely because the
mechanisms controlling atherosclerotic calcification are unknown. It has been
demonstrated that cannabinoid receptors modulate bone formation and are present in
high concentrations in atherosclerotic vessels, suggesting they may also play a role in
modulating calcification. Therefore, we tested the hypothesis that endocannabinoids
modulate calcification of plaques by affecting osteogenic trans-differentiation of vascular
smooth muscle cells (VSMC). We evaluated the effects of the two best-described
endocannabinoids (2-Arachidonoylglycerol, Anandamide) on the osteoblastic transdifferentiation of MOVAS-1 cells undergoing calcification to determine their role in the
calcification process. The MOVAS-1 cell line, a murine VSMC model was chosen as
the model because of its ability to differentiate spontaneously into osteoblast-like cells
when cultured in an osteogenic media [19].
It was observed that calcification, as detected by Alizarin Red staining, increased
in a time dependent manner in osteogenic media (Figures 3-6). Quantitation of the
Alizarin Red staining revealed that the addition of endocannabinoids to the osteogenic
media increased the amount of calcification (Figure 5 and 6). A significant increase was
19

noted with the addition of endocannabinoids when compared to the control group
(Figure 6). However, the addition of SR-144,528, a CB2 selective inhibitor, did not have
a significant effect on the degree of calcification present in the MOVAS-1 cells. These
results indicate that endocannabinoids (2AG, AEA) accelerate MOVAS-1 calcification by
a mechanism that is independent of CB2 activity. As MOVAS-1 cells also express CB1,
it is possible that this alternative mechanism stems through the activation of the CB1
receptor, or perhaps, via another uncharacterized endocannabinoid receptor.
Alternatively, 2-AG/AEA may induce calcium deposition by a mechanism that is
independent of a cell surface receptor. Further investigation is necessary to better
understand how endocannabinoids alter calcium deposition in MOVAS-1 cells.
Three osteogenic marker proteins were examined to further investigate the
effects of endocannabinoids on the osteogenic trans-differentiation of the MOVAS-1
cells. Expression of both RUNX2 and Osterix (OSX) were both minimally affected by
the endocannabinoid treatments and were not affected by the inclusion of a CB2
antagonist. This result suggests a CB2-independent effect of 2AG and AEA on the
levels of RUNX2 and OSX during MOVAS-1 calcification. Further studies to test the
effects on RUNX2 and OSX activity are needed to better determine how
endocannabinoids modulate trans-differentiation of MOVAS-1 cells. Interestingly, a
CB2-dependent effect was observed on osteopontin levels. This was evident with the
increase in OPN expression seen with the addition of endocannabinoids and the
dramatic reduction in this effect upon co-treatment with a CB2 antagonist. Future
investigation should help establish the degree by which CB2 signaling modulates
expression of OPN in MOVAS-1 cells and other VSMCs.
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In conclusion, the work in this thesis demonstrates a potential role for
endocannabinoids in moderating the lesion calcification process in atherosclerosis by
altering VSMC trans-differentiation. This study also highlights the need for further
research to investigate the CB1 and CB2 dependent effects of this process on the
development of advanced atherosclerotic lesions. Confirmation of a role for CB2 in
atherosclerotic lesion calcification would be a potentially major clarification of the littleunderstood phenomenon of advanced lesion calcification. This thesis embodies the
beginning phases of the development of an in-vitro model of the complex signaling
mechanisms involved in the endocannabinoid effect on controlling the differentiation of
VSMC. Ultimately, investigations in animal models of atherosclerosis could be
designed to test potential novel mechanisms so that the formation and calcification of
atherosclerotic plaques may be prevented or reversed. If successful, these therapies
could be applied to clinical studies targeting atherosclerotic vessels in patients and
ultimately provide some alleviation of the strain that cardiovascular diseases currently
place on our society.
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